NCT01508117: Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients |
|
|
| Terminated | 2 | 1 | US | Axitinib, AG-013736, Radiation Therapy, Hypofractionated radiation therapy | University of Cincinnati, Pfizer | Glioblastoma Multiforme | 10/12 | 10/12 | | |
NCT01533948: Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery |
|
|
| Terminated | 2 | 25 | US | axitinib, AG-013736, Inlyta, laboratory biomarker analysis | Roswell Park Cancer Institute, National Cancer Institute (NCI), National Comprehensive Cancer Network | Extraocular Extension Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma | 07/15 | 07/15 | | |
NCT01435122: A Study of Axitinib in Advanced Carcinoid Tumors |
|
|
| Completed | 2 | 30 | US | Axitinib, AG013736, selective inhibitor of receptor tyrosine kinases | H. Lee Moffitt Cancer Center and Research Institute, National Comprehensive Cancer Network, Pfizer | Carcinoid Tumor | 01/17 | 02/18 | | |
AxiGII, NCT01562197: A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma |
|
|
| Completed | 2 | 56 | Europe | axitinib, Inlyta (TM), Axitinib plus Lomustine, CCNU | Bart Neyns, Pfizer | Glioblastoma Multiforme | 08/18 | 12/18 | | |
